Treatment options for

metastatic urothelial carcinoma:

Challenge the expert

Axel Merseburger, Enrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s viewpoint to create a lively debate.

Watch these two video discussions to expand your knowledge of first- and subsequent-line immunotherapy treatment options and see how the experts work together to find possible solutions.

About this activity

Learning objectives

After studying the content, participants will be able to:

discuss current and emerging immune-based regimens for mUC and the clinical data supporting them
debate how to best integrate and sequence new immunotherapy options in the landscape of mUC to achieve optimal clinical outcomes
evaluate the importance of predictive factors to enhance patient selection and move to personalized care

Educational grant

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.

Login to access this activity

No account? Create a free account now

Email*
Password*
Enter Password Confirm Password
Healthcare Professional*
(Required) I confirm that I am a healthcare professional*
Privacy Acceptance*
(Required) I have read and accept the terms of the Privacy notice and the Terms and Conditions and consent to receive e-alerts from Springer Healthcare IME pertinent to my area of interest. I can withdraw my consent at any time by contacting IME@springer.com or via the ‘unsubscribe’ link included in any email communications*
SHE Communication Preferences
(Optional) I agree that my email address will be used by our sister site Medicine Matters Oncology, as per their Privacy Policy, for the purposes of communicating to me details of educational content pertinent to Oncology. I can withdraw my consent at any time by contacting medicinematters@springer.com or via the ‘unsubscribe’ link included in any email communications.
Email
This field is for validation purposes and should be left unchanged.

Module Content

Sections Status